Cogent Biosciences announces FDA Breakthrough Therapy Designation for bezuclastinib, a promising treatment for NonAdvanced Systemic Mastocytosis with NDA submission planned by year-end 2025.
Ideaya Biosciences shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial.
Canaccord initiates Tempus AI with Buy rating and $110 target, citing strong growth potential from AI-powered oncology testing and genomic profiling services.
GRAIL's Galleri blood test increases cancer detection by over 7-fold when added to routine screenings, catching more than 50 cancer types early when most treatable. PATHFINDER 2 study shows breakthrough results.
WeightWatchers partners with Amazon Pharmacy to offer easier access to GLP-1 weight-loss drugs like Wegovy and Zepbound, especially for customers in rural areas with faster delivery options.
Activist investor Jana Partners targets Cooper Cos., advocating for a contact lens merger with Bausch + Lomb and strategic changes to boost shareholder value amid declining performance.
